Core Laboratories (NYSE:CLB - Get Free Report) updated its first quarter 2025 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 0.120-0.160 for the period, compared to the consensus estimate of 0.210. The company issued revenue guidance of $121.0 million-$127.0 million, compared to the consensus revenue estimate of $131.7 million.
Analyst Upgrades and Downgrades
A number of brokerages have recently commented on CLB. Citigroup dropped their target price on Core Laboratories from $15.00 to $14.00 and set a "sell" rating for the company in a report on Thursday, October 31st. StockNews.com upgraded Core Laboratories from a "sell" rating to a "hold" rating in a report on Thursday, November 7th. Two analysts have rated the stock with a sell rating and three have issued a hold rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $17.00.
Get Our Latest Analysis on CLB
Core Laboratories Stock Down 0.1 %
Shares of CLB traded down $0.01 during trading hours on Wednesday, hitting $18.52. The company had a trading volume of 360,696 shares, compared to its average volume of 271,050. The company has a market capitalization of $869.42 million, a PE ratio of 28.49, a price-to-earnings-growth ratio of 1.14 and a beta of 2.39. The company has a current ratio of 2.48, a quick ratio of 1.79 and a debt-to-equity ratio of 0.55. Core Laboratories has a one year low of $13.82 and a one year high of $25.13. The company's fifty day moving average price is $19.04 and its two-hundred day moving average price is $19.50.
About Core Laboratories
(
Get Free Report)
Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Core Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Core Laboratories wasn't on the list.
While Core Laboratories currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
